[Bladder cancer].
Bladder cancer is an urologic common tumor after prostate carcinoma. Radical treatment of localized invasive tumor is based on cystectomy. Surgical mutilation could be important when Bricker's urinary derivation is performed. Moreover, delayed metastasis frequently appeared in spite of radical surgery. Thus, chemoradiotherapy is a valid alternative treatment to cystectomy for selected patients. Cisplatin or derivatives are usually concurrently administered to radiation therapy up to 60 - 65 Gy. Patients undergo control cystoscopy at midtime of treatment in order to select responders from non responders. For majority of cases, the empty bladder should be entirely treated with added margins (about 20 mm) to build the PTV. Control assessment could be improved by echography, cone beam imaging as well as bladder fiduciaries implantation before treatment. From a case report, this review summarizes the technical aspects of radiation therapy (GTV, CTV and PTV, organs at risk, planning) and main acute and late related toxicities.
Service de radiothérapie, centre régional universitaire de cancérologie Henry-S.-Kaplan CHU de Tours, Hôpital Bretonneau, 2, Boulevard Tonnellé, 37000 Tours, France.
Y
Y
Pointreau
S
S
Klotz
F
F
Denis
C
C
Durdux
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D015994:Incidence; D008297:Male; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000453:epidemiology; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000009:adverse effects / Q000379:methods; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery
D000970:Antineoplastic Agents; D002945:Cisplatin